<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501276</url>
  </required_header>
  <id_info>
    <org_study_id>ADG116-1003</org_study_id>
    <nct_id>NCT04501276</nct_id>
  </id_info>
  <brief_title>ADG116 in Patients With Advanced/Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagene Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagene Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic&#xD;
      solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that&#xD;
      specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of&#xD;
      60-90 minutes. The study is planned to treat up to 60 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumors</measure>
    <time_frame>From first dose of ADG116 (Week 1 Day 1) until 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>From first dose of ADG116 (Week 1 Day 1) to 28 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the time concentration curve (AUC) from time zero to infinity (AUC0-inf)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (peak) plasma concentration (Cmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum (peak) plasma concentration (Tmax)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Ctrough)</measure>
    <time_frame>From first dose (Cycle 1 Day 1, each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced/Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG116 Dose Escalation Level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADG116</intervention_name>
    <description>ADG116 will be administered IV over 60-90 minutes with planned doses every three weeks for the first 4 cycles. If no intolerable toxicities occur during the first consecutive four treatment cycles, administration of ADG116 may continue every 12 weeks for a total duration of up to 2 years per agreement with the Investigator and the Sponsor.</description>
    <arm_group_label>ADG116 Dose Escalation Level 1</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 2</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 3</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 4</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 5</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 6</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 7</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 8</arm_group_label>
    <arm_group_label>ADG116 Dose Escalation Level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age at the time of informed consent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no&#xD;
             deterioration over the previous 2 weeks.&#xD;
&#xD;
          -  Patients with advanced or metastatic solid tumors, confirmed by histopathology, who&#xD;
             have progressed after all standard therapies, or for whom no further standard therapy&#xD;
             exists. Patients who have declined standard therapy or have no access to standard&#xD;
             therapy may be enrolled and the reasons for lack of access need to be documented.&#xD;
&#xD;
          -  Patients who are refractory or relapsed to prior anti-CTLA4 checkpoint inhibitors or&#xD;
             anti Programmed cell death protein 1 (PD 1) will also be recruited if they meet all&#xD;
             eligibility criteria.&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Previous antitumor therapy (including endocrine, chemoradiotherapy/ radiotherapy,&#xD;
             targeted therapy, or immunotherapy) that has ended at least 4 weeks prior to&#xD;
             administration of ADG116.&#xD;
&#xD;
          -  Previous adverse events have been improved to baseline or ≤ Grade 1 NCI CTCAE v5.0&#xD;
             (except for patients with alopecia).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  Treatment with any investigational drug within 4 weeks prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Grade ≥ 3 immune-related AEs (irAEs) or irAE that lead to discontinuation of prior&#xD;
             immunotherapy.&#xD;
&#xD;
          -  Patients with active autoimmune disease or a documented medical history of autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Patients requiring systemic treatment with corticosteroids or other immunosuppressive&#xD;
             medications within 21 days before the planned first dose of study drug.&#xD;
&#xD;
          -  Active viral (any etiology) hepatitis patient are excluded.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) positive status.&#xD;
&#xD;
          -  Patients with any type of primary immunodeficiency or autoimmune disorder requiring&#xD;
             treatment.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to the first dose of the study drug.&#xD;
&#xD;
          -  Clinically significant cardiac conditions.&#xD;
&#xD;
          -  Pulmonary embolism or deep vein thrombosis within 3 months prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Any known, documented, or suspected history of illicit substance abuse.&#xD;
&#xD;
          -  Any other disease or clinically significant abnormality in laboratory parameters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristine She</last_name>
    <phone>4088389296</phone>
    <email>kristine_she@adagene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Gong</last_name>
    <phone>8586954033</phone>
    <email>hua_gong@adagene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761049s003lbl.pdf</url>
    <description>BAVENCIO (avelumab), [package insert]. EMD Serono, Inc. and Pfizer Inc., NY. 2017.</description>
  </link>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf</url>
    <description>IMFINZI (Durvalumab), [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2017.</description>
  </link>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s037lbl.pdf</url>
    <description>KEYTRUDA (pembrolizumab), [package insert]. Merck Sharp &amp; Dohme Corp. Whitehouse Station, NJ.2014.</description>
  </link>
  <reference>
    <citation>Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.</citation>
    <PMID>29442540</PMID>
  </reference>
  <reference>
    <citation>Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3. Review.</citation>
    <PMID>29769148</PMID>
  </reference>
  <reference>
    <citation>Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30. Erratum in: J Clin Oncol. 2012 Oct 10;30(29):3654.</citation>
    <PMID>22547592</PMID>
  </reference>
  <reference>
    <citation>Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007 Feb;7(2):95-106. Review.</citation>
    <PMID>17251916</PMID>
  </reference>
  <reference>
    <citation>Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.</citation>
    <PMID>22858559</PMID>
  </reference>
  <reference>
    <citation>Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012 Sep;23 Suppl 8:viii6-9. doi: 10.1093/annonc/mds256. Review.</citation>
    <PMID>22918931</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced/Metastatic Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

